Janus Henderson Global Life Sciences FundJNGLX
Type
Mutual fund
Peer group
US equity: Healthcare
Net assets
$5.2B
Expense ratio
0.81%
1-year return
+37.1%
3 years, a year
+16.8%
5 years, a year
+9.5%
12-month yield
4.20%
Holdings
104
What it aims to do.
Janus Henderson Global Life Sciences Fund seeks long-term growth of capital.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| LLY Eli Lilly & Co. | 8.84% |
| JNJ Johnson & Johnson | 7.29% |
| AZN AstraZeneca PLC | 4.59% |
| ABBV AbbVie Inc. | 4.05% |
| UNH UnitedHealth Group Inc. | 3.13% |
| NVS Novartis AG | 2.86% |
| TMO Thermo Fisher Scientific Inc | 2.51% |
| PRAX Praxis Precision Medicines Inc | 2.45% |
| ARGX Argenx SE | 2.40% |
| ABT Abbott Laboratories | 2.40% |
More on JNGLX.
- JNGLX overview
- JNGLX holdings
- JNGLX risk
- JNGLX costs
- JNGLX money in and out
- JNGLX share classes
- Compare JNGLX with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.